Endpoints News

A top HHS official says TrumpRx isn’t meant for mass adoption, but rather to improve drug price transparency and support negotiations. endpoints.news/top-hhs-offici…

AI biotech Earendil raised $787M to scale its drug discovery platform and is reportedly weighing a Hong Kong IPO. endpoints.news/china-rooted-a…

Novartis bets $2B upfront to upgrade its own breast cancer franchise with a next-gen Piqray. endpoints.news/novartis-to-pa…

Genentech pulls the plug on muscle-preserving drug in genetic diseases — and now its obesity trial is under scrutiny. endpoints.news/genentech-cull…

The FDA approved a higher-dose Wegovy, giving Novo Nordisk a faster-than-usual green light via a commissioner’s voucher as it pushes to stay competitive in obesity. endpoints.news/novo-wins-fda-…

Pfizer scored a Phase 3 win for Talzenna plus Xtandi in prostate cancer, cutting the risk of progression or death and paving the way for earlier use of the PARP inhibitor. endpoints.news/pfizer-seeks-e…

⚡ Exclusive: Verily becomes 'independent company' with $300M raise endpoints.news/verily-raises-…

AstraZeneca is expanding its China push with a new cell therapy R&D hub and manufacturing plans in Shanghai, deepening UK-China ties as it invests $15B in the region. endpoints.news/astrazeneca-de…

Exclusive: Congruence Therapeutics, founded by Clarissa Desjardins, raised $40M and has taken its lead obesity drug into the clinic, marking a key step for the company. endpoints.news/congruence-sta…

Lilly’s triple-G retatrutide matched Mounjaro on blood sugar control in its first Phase 3 diabetes readout, while delivering stronger weight loss. endpoints.news/lillys-triple-…

With $68.7M in hand, Excalipoint is banking on China's trial speed to win the T cell engager race. endpoints.news/shanghai-biote…

Xaira tests scaling laws in virtual cells after its first AI model release. endpoints.news/xaira-unveils-…

Bicycle to trim 30% of staff after cancer drug's regulatory setback. endpoints.news/bicycle-to-cut…

Tomorrow at noon ET: The patent cliff is closing in — and the dealmaking math is shifting fast. With $180B in revenue at risk and markets reopening, M&A is heating up as bidding wars return and policy changes reshape the landscape. Join @ArmstrongDrew, along with @FT’s Patrick Temple-West and Oliver Barnes, for a quick breakdown of what’s next. Register to watch for free: capitalcompetitionpatent.live.ft.com/?utm_source=li… @ftlive

Rhythm takes a Phase 3 hit on Imcivree just as the FDA closes in on its bigger obesity decision. endpoints.news/rhythms-imcivr…

New renal disease biotech R1 Therapeutics raises $77.5M for Phase 2b. endpoints.news/new-renal-dise…

J&J continues to quietly pull back from its JLABS incubator program — and New York is the latest city to lose its spot. endpoints.news/jj-pulls-out-o…

New ADC data from CytomX in colorectal cancer; FDA expands Cosentyx's reach for Novartis. endpoints.news/cytomx-reports…